Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and ExpositionGlobeNewsWire • 11/04/21
Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 11/02/21
Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 11/01/21
Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate UpdateGlobeNewsWire • 10/25/21
Clinical Data from Editas Medicine's Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual CongressGlobeNewsWire • 10/20/21
Tuesday Afternoon Analyst Upgrades and Downgrades: CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and More24/7 Wall Street • 10/19/21
Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves SuccessfulInvestorPlace • 10/19/21
Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual MeetingGlobeNewsWire • 10/07/21
Editas Medicine, Inc (EDIT) Management Presents at Chardan's 5th Annual Genetic Medicines Conference (Transcript)Seeking Alpha • 10/04/21
Editas Medicine to Present at Chardan's 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/30/21
Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder CandidateBenzinga • 09/29/21